Verona Pharma PLC (VRNA) Company Sales Revenue

Verona Pharma - graphic logo of issuer VRNA

Short-term expectations for Verona Pharma plc (VRNA) depend on the rollout pace of its new COPD product. The company's sales chart demonstrates current dynamics, where 0.22 serves as the base parameter value. Strong pricing power is driven by the unique mechanism of Ohtuvayre, although fierce competition with global behemoths in the inhalation niche creates significant barriers to business expansion.

VRNA - Verona Pharma Revenue and Sales Volume over the range 07/04/2022 - 10/18/2025

Analytical breakdowns for Verona Pharma plc

- market price and analyst price targets:
Comprehensive company analysis:Verona Pharma plc VRNA
Flagship merchandise of Verona Pharma plc

Investors must evaluate the asset's fundamental stability by analyzing actual cash inflows. This metric captures daily customer revenue, excluding speculative expectations and demonstrating real income. The company's execution history allows an auditor to verify the efficiency of operational management. For Verona Pharma plc (VRNA), growth in this metric confirms strong pricing power during the rollout of Ohtuvayre. Inelastic demand for the innovative drug ensures a steady cash inflow.

Key competitors

HLN: Company Sales Revenue|Company Revenue Kenvue (KVUE)|MENS (Jyong Biotech Limited) - Company Sales Revenue|Company Revenue Ligand Pharma LGND|Revenue and Sales Volume Amneal Corp AMRX|Perrigo Company PLC - Revenue and Sales Volume|ALVO: Company Revenue|liquidia.com (LQDA) - Company Revenue|GLPG (Galapagos) - Company Revenue|Company Sales ANIP|Company Sales Volume MNKD (Afrezza)|Revenue and Sales Volume AMPH|PCRX (Pacira BioSciences) - Company Sales Revenue|Revenue and Sales Volume SPRY (ARS Pharmaceuticals, Inc.)|Theravance Biopharma, Inc. - Company Revenue|Aquestive Corp - Revenue and Sales Volume|scpharmaceuticals.com (SCPH) - Company Sales|TECX: Revenue and Sales Volume|Tonix Pharmaceuticals - Company Sales Revenue|Company Sales SXTC|EPRX: Company Sales Revenue|Company Sales BHST (BioHarvest Sciences Inc.)|Company Gross Revenue Invizyne|Company Revenue Oramed Pharmaceuticals ORMP|Company Sales Revenue ENTX|HYFT - Company Revenue|Company Sales Revenue ABVC (ABVC BioPharma Inc.)|CPIX: Revenue and Sales Volume|Quantum BioPharma Limited - Company Sales Revenue|FGEN (FibroGen Corp) - Revenue and Sales Volume|Revenue and Sales Volume Telomir Pharmaceuticals|Revenue and Sales Volume RANI|SNYR (Synergy CHC Corp.) - Company Sales Revenue|Revenue and Sales Volume RLYB (Rallybio Corp)|LEXX: Company Sales Volume|PULM - Company Revenue|PTHL: Company Revenue|APM (aptorumgroup.com) - Company Sales|Lyra Therapeutics - Company Sales Revenue|Company Revenue Impact BioMedical Inc|TNF Pharmaceuticals, Inc. (TNFA) - Company Gross Revenue|Revenue and Sales Volume YCBD|PRFX: Company Annual Revenue|Company Revenue altamiratherapeutics.com CYTO|Revenue and Sales Volume Lipella Pharmaceuticals Inc LIPO|OPTN - Company Revenue|Company Gross Revenue Pieris Pharma PIRS|Procaps Group SA (PROC) - Company Revenue|Company Annual Revenue PTPI (Petros Pharmaceuticals, Inc.)|QLI (Qilian International Holding) - Revenue and Sales Volume|SLRN: Company Sales Revenue|Revenue and Sales Volume TFFP